| Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 | Cell | 2020 | 2.2K |
| Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases | Translational Research | 2020 | 1.3K |
| Clinical Characteristics of Covid-19 in New York City | New England Journal of Medicine | 2020 | 1.3K |
| Targeting potential drivers of COVID-19: Neutrophil extracellular traps | Journal of Experimental Medicine | 2020 | 795 |
| Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | New England Journal of Medicine | 2020 | 778 |
| Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability | Science | 2020 | 724 |
| SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract | Cell | 2020 | 710 |
| Initial Invasive or Conservative Strategy for Stable Coronary Disease | New England Journal of Medicine | 2020 | 642 |
| Severe Covid-19 | New England Journal of Medicine | 2020 | 613 |
| Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium | Clinical Infectious Diseases | 2020 | 607 |
| Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome | Blood | 2020 | 581 |
| COVID-19 in solid organ transplant recipients: Initial report from the US epicenter | American Journal of Transplantation | 2020 | 474 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials | Lancet Oncology, The | 2020 | 454 |
| Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US | JAMA Internal Medicine | 2020 | 426 |
| Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series | BMJ, The | 2020 | 423 |
| Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study | Lancet Oncology, The | 2020 | 402 |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia | Leukemia | 2020 | 356 |
| The Variety of Cardiovascular Presentations of COVID-19 | Circulation | 2020 | 343 |
| A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids | Cell Stem Cell | 2020 | 338 |
| Determinants of COVID-19 disease severity in patients with cancer | Nature Medicine | 2020 | 329 |
| Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC | New England Journal of Medicine | 2020 | 317 |
| Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza | JAMA Neurology | 2020 | 312 |
| The evolutionary history of 2,658 cancers | Nature | 2020 | 307 |
| Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers | Cell | 2020 | 288 |
| Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials | Lancet Oncology, The | 2020 | 279 |
